- Home
- CREV vs XBIO Comparison
CREV vs XBIO Comparison
Compare CREV & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- XBIO
- Stock Information
- Founded
- CREV 2007
- XBIO N/A
- Country
- CREV Ireland
- XBIO United States
- Employees
- CREV N/A
- XBIO N/A
- Industry
- CREV
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- XBIO Health Care
- Exchange
- CREV Nasdaq
- XBIO Nasdaq
- Market Cap
- CREV 7.2M
- XBIO 5.8M
- IPO Year
- CREV N/A
- XBIO N/A
- Fundamental
- Price
- CREV $2.76
- XBIO $3.39
- Analyst Decision
- CREV Strong Buy
- XBIO Hold
- Analyst Count
- CREV 1
- XBIO 1
- Target Price
- CREV $39.00
- XBIO N/A
- AVG Volume (30 Days)
- CREV 25.5K
- XBIO 4.5K
- Earning Date
- CREV 01-01-0001
- XBIO 03-20-2025
- Dividend Yield
- CREV N/A
- XBIO N/A
- EPS Growth
- CREV N/A
- XBIO N/A
- EPS
- CREV N/A
- XBIO N/A
- Revenue
- CREV $39,261,077.00
- XBIO $2,523,427.00
- Revenue This Year
- CREV $40.76
- XBIO N/A
- Revenue Next Year
- CREV $86.18
- XBIO N/A
- P/E Ratio
- CREV N/A
- XBIO N/A
- Revenue Growth
- CREV 41.52
- XBIO 7.15
- 52 Week Low
- CREV $2.00
- XBIO $2.78
- 52 Week High
- CREV $22.34
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- CREV 34.70
- XBIO 28.12
- Support Level
- CREV $2.72
- XBIO $3.80
- Resistance Level
- CREV $3.79
- XBIO $3.81
- Average True Range (ATR)
- CREV 0.22
- XBIO 0.16
- MACD
- CREV -0.02
- XBIO -0.05
- Stochastic Oscillator
- CREV 4.30
- XBIO 16.08
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.